Last reviewed · How we verify
ASTX727 SD
At a glance
| Generic name | ASTX727 SD |
|---|---|
| Also known as | oral decitabine (SD) + cedazuridine (E7727) |
| Sponsor | Taiho Oncology, Inc. |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment Within myeloMATCH (MyeloMATCH Screening Trial) (PHASE2)
- Testing the Combination of Nivolumab and ASTX727 for Relapsed or Refractory B-Cell Lymphoma (PHASE1)
- Testing the Addition of an IDH2 Inhibitor, Enasidenib, to Usual Treatment (Cedazuridine-Decitabine) for Higher-Risk Myelodysplastic Syndrome (MDS) With IDH2 Mutation (A MyeloMATCH Treatment Trial) (PHASE2)
- Phase 1-2 Study of Low Dose ASTX727 (ASTX727 LD) in Lower Risk MDS (PHASE1, PHASE2)
- A Study for Participants Who Participated in Prior Clinical Studies of ASTX727 (Standard Dose) (PHASE2)
- Study of the Safety, Tolerability and Efficacy of KPT-8602 in Participants With Relapsed/Refractory Cancer Indications (PHASE1, PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- ASTX727 SD CI brief — competitive landscape report
- ASTX727 SD updates RSS · CI watch RSS
- Taiho Oncology, Inc. portfolio CI